BCL2 and ovarian carcinoma: It was shown that HMGA2 silencing promotes apoptosis by reducing antiapoptotic Bcl-2 expression in ovarian cancer [34] and we found that HMGA2 derepresses the expression of Bcl-2 by inhibiting miR-34a in breast cancer, thereby promoting the Bcl-2 antiapoptotic pathway [65].